NCT04216524 2026-03-04
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
3 trialsNCT07007052 2025-11-26
TAGVEN
French Innovative Leukemia Organisation
Phase 2 Not yet recruiting
NCT03113643 2025-11-04
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Dana-Farber Cancer Institute
Phase 1 Recruiting